Compare TWST & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWST | LGND |
|---|---|---|
| Founded | 2013 | 1987 |
| Country | United States | United States |
| Employees | N/A | 68 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.7B |
| IPO Year | 2018 | N/A |
| Metric | TWST | LGND |
|---|---|---|
| Price | $44.49 | $195.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $48.75 | ★ $245.86 |
| AVG Volume (30 Days) | ★ 903.2K | 183.6K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.89 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $376,572,000.00 | N/A |
| Revenue This Year | $18.91 | $1.50 |
| Revenue Next Year | $15.07 | $18.28 |
| P/E Ratio | ★ N/A | $76.27 |
| Revenue Growth | ★ 20.32 | N/A |
| 52 Week Low | $23.30 | $93.58 |
| 52 Week High | $57.88 | $227.92 |
| Indicator | TWST | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 46.04 | 44.28 |
| Support Level | $41.65 | $179.55 |
| Resistance Level | $45.76 | $207.72 |
| Average True Range (ATR) | 2.66 | 10.02 |
| MACD | -0.06 | -1.59 |
| Stochastic Oscillator | 26.56 | 3.39 |
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.